1: Letai A. Functional precision cancer medicine-moving beyond pure genomics. Nat
Med. 2017 Sep 8;23(9):1028-1035. doi: 10.1038/nm.4389. PubMed PMID: 28886003.


2: Hafner A, Stewart-Ornstein J, Purvis JE, Forrester WC, Bulyk ML, Lahav G. p53 
pulses lead to distinct patterns of gene expression albeit similar DNA-binding
dynamics. Nat Struct Mol Biol. 2017 Aug 21. doi: 10.1038/nsmb.3452. [Epub ahead
of print] PubMed PMID: 28825732.


3: Hata AN, Rowley S, Archibald HL, Gomez-Caraballo M, Siddiqui FM, Ji F, Jung J,
Light M, Lee JS, Debussche L, Sidhu S, Sadreyev RI, Watters J, Engelman JA.
Synergistic activity and heterogeneous acquired resistance of combined MDM2 and
MEK inhibition in KRAS mutant cancers. Oncogene. 2017 Aug 7. doi:
10.1038/onc.2017.258. [Epub ahead of print] PubMed PMID: 28783173.


4: Kabraji S, Solé X, Huang Y, Bango C, Bowden M, Bardia A, Sgroi D, Loda M,
Ramaswamy S. AKT1(low) quiescent cancer cells persist after neoadjuvant
chemotherapy in triple negative breast cancer. Breast Cancer Res. 2017 Aug
1;19(1):88. doi: 10.1186/s13058-017-0877-7. PubMed PMID: 28764807; PubMed Central
PMCID: PMC5540189.


5: Chakrabarti S, Michor F. Pharmacokinetics and Drug Interactions Determine
Optimum Combination Strategies in Computational Models of Cancer Evolution.
Cancer Res. 2017 Jul 15;77(14):3908-3921. doi: 10.1158/0008-5472.CAN-16-2871.
Epub 2017 May 31. PubMed PMID: 28566331; PubMed Central PMCID: PMC5553595.


6: Mouw KW, Goldberg MS, Konstantinopoulos PA, D'Andrea AD. DNA Damage and Repair
Biomarkers of Immunotherapy Response. Cancer Discov. 2017 Jul;7(7):675-693. doi: 
10.1158/2159-8290.CD-17-0226. Epub 2017 Jun 19. Review. PubMed PMID: 28630051.


7: Gil Del Alcazar CR, Huh SJ, Ekram MB, Trinh A, Liu LL, Beca F, Zi X, Kwak M,
Bergholtz H, Su Y, Ding L, Russnes HG, Richardson AL, Babski K, Min Hui Kim E,
McDonnell C, Wagner J, Rowberry R, Freeman GJ, Dillon D, Sorlie T, Coussens LM,
Garber JE, Fan R, Bobolis K, Allred DC, Jeong J, Park SY, Michor F, Polyak K.
Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition.
Cancer Discov. 2017 Jun 26. pii: CD-17-0222. doi: 10.1158/2159-8290.CD-17-0222.
[Epub ahead of print] PubMed PMID: 28652380.


8: Hafner M, Niepel M, Sorger PK. Alternative drug sensitivity metrics improve
preclinical cancer pharmacogenomics. Nat Biotechnol. 2017 Jun 7;35(6):500-502.
doi: 10.1038/nbt.3882. PubMed PMID: 28591115.


9: Cortes-Ciriano I, Lee S, Park WY, Kim TM, Park PJ. A molecular portrait of
microsatellite instability across multiple cancers. Nat Commun. 2017 Jun
6;8:15180. doi: 10.1038/ncomms15180. PubMed PMID: 28585546; PubMed Central PMCID:
PMC5467167.


10: Severson E, Arnett KL, Wang H, Zang C, Taing L, Liu H, Pear WS, Shirley Liu
X, Blacklow SC, Aster JC. Genome-wide identification and characterization of
Notch transcription complex-binding sequence-paired sites in leukemia cells. Sci 
Signal. 2017 May 2;10(477). pii: eaag1598. doi: 10.1126/scisignal.aag1598. PubMed
PMID: 28465412.


11: Stewart-Ornstein J, Lahav G. p53 dynamics in response to DNA damage vary
across cell lines and are shaped by efficiency of DNA repair and activity of the 
kinase ATM. Sci Signal. 2017 Apr 25;10(476). pii: eaah6671. doi:
10.1126/scisignal.aah6671. PubMed PMID: 28442631; PubMed Central PMCID:
PMC5504473.


12: Najafov A, Chen H, Yuan J. Necroptosis and Cancer. Trends Cancer. 2017
Apr;3(4):294-301. doi: 10.1016/j.trecan.2017.03.002. PubMed PMID: 28451648;
PubMed Central PMCID: PMC5402749.


13: Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the
management of cancer and other diseases. Nat Rev Drug Discov. 2017
Mar;16(3):203-222. doi: 10.1038/nrd.2016.246. Epub 2017 Feb 17. Review. PubMed
PMID: 28209991.


14: Li H, Mar BG, Zhang H, Puram RV, Vazquez F, Weir BA, Hahn WC, Ebert B,
Pellman D. The EMT regulator ZEB2 is a novel dependency of human and murine acute
myeloid leukemia. Blood. 2017 Jan 26;129(4):497-508. doi:
10.1182/blood-2016-05-714493. Epub 2016 Oct 18. PubMed PMID: 27756750; PubMed
Central PMCID: PMC5270388.